With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products... Show more
NVO is expected to report earnings to fall 20.31% to 76 cents per share on November 04
Q3'26
Est.
$0.76
Q2'26
Beat
by $0.17
Q1'26
Missed
by $0.05
Q4'25
Beat
by $0.10
Q3'25
Missed
by $0.09
The last earnings report on August 04 showed earnings per share of 95 cents, beating the estimate of 78 cents. With 10.26M shares outstanding, the current market capitalization sits at 169.50B.